WebThe implementation of the GCC centralized procedure (CP) was subject to criticisms, with challenges both from the phar-maceutical industry who were apprehensive about whether the GCC-DR would be an obstacle to the timely approval of med-icines in the region as well as from government officials who were concerned about losing sovereignty to the CP.2 WebJul 19, 2024 · Background: The Gulf Centralised Committee for Drug Registration (GCC-DR), as part of the Gulf Health Council (GHC), enables the consolidated registration of pharmaceutical products throughout the member states of the Gulf Cooperation Council. Objectives: The objectives of this study were to provide an update of the performance of …
Evaluation of the Performance of the Gulf Cooperation Council ...
WebThe aim of this study was to examine the views and experiences of the Gulf Cooperation Council (GCC) states and pharmaceutical companies to identify the strengths and … WebJan 1, 2012 · The aim of the study was to evaluate the Gulf Cooperation Council (GCC) centralized regulatory review process. Regulatory review times—including submission … scaffold sales
The Gulf States Assessment and Experience with the Centralised Procedure
WebDec 30, 2015 · The aim of this study was to examine the views and experiences of the Gulf Cooperation Council (GCC) states and pharmaceutical companies to identify the strengths and weaknesses of the GCC centralized registration procedure (GCC-CP). WebUnder the centralised authorisation procedure, pharmaceutical companies submit a single marketing-authorisation application to EMA. This allows the marketing-authorisation holder to market the medicine and make it available to patients and healthcare professionals throughout the EU on the basis of a single marketing authorisation.. EMA's Committee … WebSep 18, 2016 · Introduction. The historical implementation of the central registration system was subject to several criticisms with challenges from both the pharmaceutical industry and government. The GCC-DR … scaffold science